Lantheus Holdings, Inc.

LNTH

US5165441032

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
62.33 ^USD	+1.38%		+1.35%	+0.53%

Apr. 18	B. Riley Raises Price Target on Lantheus Holdings to $99 From $95, Keeps Buy Rating	MT
Mar. 07	Lantheus Holdings Insider Sold Shares Worth $262,005, According to a Recent SEC Filing	MT

Lantheus Holdings, Inc. Provides Revenue Guidance for the Third Quarter of 2021

July 28, 2021 at 07:44 am EDT

Lantheus Holdings, Inc. provided revenue guidance for the third quarter of 2021. For the quarter, the company expects revenue to be in the range of $95 million to $100 million.

Latest news about Lantheus Holdings, Inc.

B. Riley Raises Price Target on Lantheus Holdings to $99 From $95, Keeps Buy Rating	Apr. 18	MT
Lantheus Holdings Insider Sold Shares Worth $262,005, According to a Recent SEC Filing	Mar. 07	MT
Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc. and other investors	Mar. 05	CI
Lantheus Holdings Says FDA Approves Expanded Use of Definity in Pediatric Patients	Mar. 04	MT
Lantheus Holdings, Inc. Announces the FDA Approval of Definity (Perflutren Lipid Microsphere) for Pediatric Patients	Mar. 04	CI
Perspective Therapeutics, Inc. announced that it expects to receive $87.409482 million in funding from Lantheus Holdings, Inc. and other investors	Mar. 03	CI
Lantheus Names Amanda Morgan Chief Commercial Officer	Feb. 28	MT
Truist Adjusts Price Target on Lantheus Holdings to $82 From $80, Maintains Buy Rating	Feb. 26	MT
Sector Update: Health Care Stocks Advance Pre-Bell Thursday	Feb. 22	MT
Lantheus Holdings Q4 Adjusted Earnings, Revenue Climb; Issues Q1, Full Year Guidance; Shares Rise	Feb. 22	MT
Transcript : Lantheus Holdings, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
(LNTH) LANTHEUS HOLDINGS Forecasts Q1 EPS Range $1.50 - $1.54	Feb. 22	MT
(LNTH) LANTHEUS HOLDINGS Forecasts Fiscal Year 2024 EPS Range $6.50 - $6.70	Feb. 22	MT
Earnings Flash (LNTH) LANTHEUS HOLDINGS Reports Q4 Revenue $354M	Feb. 22	MT
Earnings Flash (LNTH) LANTHEUS HOLDINGS Reports Q4 EPS $1.75	Feb. 22	MT
Lantheus Holdings, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024	Feb. 22	CI
Lantheus Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Lantheus Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Lantheus to Supply Imaging Agent for Alzheimer's Study	Feb. 13	MT
Lantheus Holdings, Inc. Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging	Feb. 13	CI
Sector Update: Health Care Stocks Stronger Late Afternoon	Jan. 26	MT
Lantheus Sued by Novartis Entities for Patent Infringement	Jan. 26	MT
Sector Update: Health Care Stocks Higher Friday Afternoon	Jan. 26	MT
Sector Update: Health Care	Jan. 26	MT
Lantheus Sued by Novartis Entities for Patent Infringement	Jan. 26	MT

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company. The Company is engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, NEUROLITE, Xenon-133, CARDIOLITE, RELISTOR, Automated Bone Scan Index, and others. Its commercial products are used by cardiologists, internal medicine physicians, and others.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-04-25 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Lantheus Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

62.33 USD

Average target price

94.11 USD

Spread / Average Target

+50.99%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
LANTHEUS HOLDINGS, INC.	+0.53%	4.21B
BIOMÉRIEUX	-1.59%	12.58B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-17.62%	6.82B
DIASORIN S.P.A.	-3.93%	5.14B
AUTOBIO DIAGNOSTICS CO., LTD.	-6.68%	4.22B
10X GENOMICS, INC.	-48.27%	3.47B
ANDON HEALTH CO., LTD.	+7.09%	2.65B
VITROLIFE AB	-13.71%	2.25B
MYRIAD GENETICS, INC.	-3.40%	1.69B
SHANGHAI RUNDA MEDICAL TECHNOLOGY CO., LTD.	-12.04%	1.48B

Diagnostic & Testing Substances